Lipocine announces first patient dosed in phase 3 clinical trial for lpcn 1154 in postpartum depression

Phase 3 top line results expected q2 2026 salt lake city , june 26, 2025 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that the first patient has been dosed in its pivotal phase 3 clinical trial of lpcn 1154 (oral brexanolone), its investigational oral treatment for postpartum depression (ppd). following fda feedback, this study is being conducted in an outpatient setting, with no requirement for medical monitoring by a healthcare provider.
LPCN Ratings Summary
LPCN Quant Ranking